The Warsaw office of Greenberg Traurig has advised MBank as the manager of the offering in the accelerated bookbuilding process of Mabion’s PLN 130 million newly issued shares. White & Case reportedly advised the issuer.
According to Greenberg Traurig, “the investors have declared their subscription for all offered 2.43 million shares and the issue price has been set nearly 2.5 times higher than the minimum price calculated in accordance with the authorization expressed in the resolution of the extraordinary general meeting of the company.”
Mabion is a Polish biotechnology company active in the development and implementation of biotech drugs based on monoclonal antibody technology. According to Greenberg Traurig, in March 2021 Mabion entered into a framework agreement with Novavax regarding the production of technical batches of antigen for Novavax’s Covid-19 vaccine candidate.
Greenberg Traurig’s team consisted of Partner Pawel Piotrowski and Associate Jakub Tarlowski.
